Appili Austausch ISIN: CA03783R1073 Forum: Aktien User: Nasemütze

endlich mal ein Lichtblick heute

Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the company secured a commitment for the second stage of funding for ATI-1701 from the U.S. Air Force Academy (“USAFA”), who is working in partnership with the Defense Threat Reduction Agency (“DTRA”), the funding agency. ATI-1701 is the Company’s potential first-in-class vaccine candidate for the prevention of infection with Francisella tularensis, the causative agent of tularemia and a top-priority biothreat. With this additional 6.6 million award, Appili’s ATI-1701 program has been awarded the total US$14 million in USAFA funding commitments announced on May 8, 2023.

was für eine Gurke, fällt wieder ... Börse ist nur noch zum Abgewöhnen

https://www.stocktitan.net/news/APLIF/appili-therapeutics-presents-at-the-10th-international-tularemia-cea6wkf3qa53.html

👍

https://finance.yahoo.com/news/appili-therapeutics-announces-u-fda-115400400.html

😎

👍

https://finance.yahoo.com/news/aplif-executes-initial-contract-usafa-131500486.html

Nur noch 50% - 🙏

mano, hätt ich mal bei 0,03 nachgekauft ...

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the Company has executed the initial contract with the U.S. Air Force Academy (USAFA) for the previously announced funding of the ATI-1701 program. This contract represents the first stage of funding from the previously announced award from the U.S. Department of Defense (“DOD”). This initial funding, in the amount of US$7.3 million, will be used to kick-off ATI-1701 early-stage development and regulatory activities. As the initial activities progress, Appili will be engaging USAFA for additional tranches of funding to continue development through IND. ATI-1701, our biodefense vaccine candidate, is the Company’s potential first-in-class vaccine candidate for the prevention of infection with Francisella tularensis, the causative agent of tularemia and a top-priority biothreat.

https://ceo.ca/@businesswire/appili-therapeutics-secures-contract-for-ati-1701-funding

Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Dr. Don Cilla, Appili President and Chief Executive Officer, will present at the Bloom Burton & Co. Healthcare Investor Conference taking place on April 25 and 26, 2023. The presentation will include an update on Appili’s pipeline of novel anti-infectives; ATI-1701, a vaccine for tularemia being funded by the U.S. Government through IND submission and ATI-1801, a treatment for cutaneous leishmaniasis, a disfiguring infection of the skin. Appili believes that both programs may be eligible to receive FDA Priority Review Vouchers upon approval.

https://financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/appili-therapeutics-appoints-dr-gary-nabors-as-chief-development-officer